Category: Infused Products & Extracts

Isodiol International Inc. Signs Licensing Agreement With Level Brands Inc And Its Chairman Emeritus And Chief Brand Strategist Kathy Ireland

SHARE THIS POST Isodiol to begin marketing new line of phytoceutical products for kathy ireland® Health & Wellness and Ireland Men One January 8, 2018 – Vancouver, BC – Isodiol International Inc., (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a licensing agreement with Level Brands Inc. (NYSE: LEVB), an innovative marketing and licensing company that provides bold, unconventional and socially responsible branding for leading businesses. Under the agreement, Isodiol will work with Level Brands to develop consumer products for its subsidiaries, kathy ireland® Health & Wellness and Ireland Men One (I’M1), the company’s lifestyle brand for men.  Encore Endeavor One (EE1), Level Brands’ corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines. “We look forward to incorporating Kathy Ireland’s proven genius into Isodiol’s existing product strategy,” says Marcos Agramont, CEO of Isodiol.  “With more than 17,000 diverse offerings in the product line, Kathy Ireland has earned the confidence of millions and we are excited to introduce those consumers to the Isodiol brand.  She will bring tremendous energy into this burgeoning field and we look forward to working with her and the Level Brands’ team to provide safe, consistent, and highly bioactive cannabinoid products to the ever-expanding market.” kathy...

Read More

Creso Pharma Market Update

Highlight Creso completes due diligence for Mernova Medicinal Inc.’s Canadian medicinal cannabis growing facility Construction contract signed, ground works commenced in Canada and project is on track for completion in Q3 2018 Canada amends the Cannabis Act. Bill C-45 to allow edible cannabis products in 2019; opportunities for Creso’s cannaQIX® and cannapeal® product ranges Over 200,000 patients now registered for medicinal cannabis in Canada Nova Scotia opens public consultation on medicinal cannabis Mernova Medicinal and Creso join 16 other licenced producers and Ad Standards group to further self-regulation for the industry Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to provide this market update: Due diligence completed for medicinal cannabis growing facility Creso has successfully completed due diligence on the Mernova Medicinal Inc. acquisition, a 20,000 square foot medical cannabis growing facility in Nova Scotia, Canada. Also, the application for a medical cannabis cultivation licence under Health Canada’s Access to Cannabis for Medical Purposes Regulation (ACMPR) program is progressing. It will give Creso a significant competitive advantage as one of the few companies globally and the only medicinal cannabis company listed on the ASX with 100% ownership and capacity to cultivate, extract and manufacture its own innovative cannabis and hemp derived human and animal therapeutic products in Canada. These products will be for local distribution as well as export to countries which accept cannabis and hemp imports....

Read More